FCGRT

Fc fragment of IgG receptor and transporter

Score: 0.675 Price: $0.68 Medium Druggability Status: active Wiki: FCGRT

🧠 Neurodegeneration

HYPOTHESES

PAPERS

KG EDGES

DEBATES

3D Protein Structure

🧬 FCGRT — PDB 1I1A Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

Medium

Score: 0.51

Clinical Stage

Approved

Target Class

Transporter

Safety

0.70

Druggability Analysis

Drug Development0.75

Structural Tractability0.85

Target Class0.70

Safety Profile0.70

Key Metrics

PDB Structures:

Known Drugs:

Approved:

In Clinical Trials:

Drug Pipeline (1 compounds)

1 Approved

Therapeutic Areas:

Autoimmune disorders (myasthenia gravis, CIDP) Multiple sclerosis and neuroinflammatory diseases Neuromyelitis optica spectrum disorder Autoimmune hemolytic anemia IgG-mediated neurodegeneration

Druggability Rationale: FCGRT is highly druggable (score: 0.90) due to its well-characterized structure (24 PDB entries, 1.85 Å resolution), validated by the FDA-approved monoclonal antibody efgartigimod for myasthenia gravis. As a cell-surface transporter with extracellular epitopes, it is ideally suited for antibody-based therapeutics that can block FcRn-mediated IgG recycling without requiring intracellular penetration.

Mechanism: Monoclonal antibody blocking FcRn-mediated IgG recycling

Drug Pipeline (1 compounds)

1 Approved

Known Drugs:

efgartigimod (approved) — myasthenia gravis

Structural Data:

PDB (24) ✓AlphaFold ✓Cryo-EM ✓

3M17 3M1B 4K71 4N0U 5BJT+19 more

UniProt: A0AB39TYH5

Binding Pocket Analysis:

The FcRn binding pocket is a pH-dependent interaction site located in the extracellular domain that accommodates the Fc region of IgG (exemplified by PDB 3M17, 3M1B); the pocket features histidine residues crucial for pH-sensitive binding at endosomal pH (~6.0) versus neutral pH, making it an ideal epitope for competitive monoclonal antibodies like efgartigimod.

🧬 3D Protein Structure

🧬 FCGRT — PDB 1I1A Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

Selectivity is less challenging for antibody-based FcRn modulators compared to small molecules, as the target lacks major tissue isoforms and the extracellular domain is immunologically distinct. However, off-target effects may include modulation of albumin recycling and systemic IgG reduction, requiring careful monitoring of immune homeostasis.